Drug Trial Radar · NCT07238868
An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy
Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
144
Planned (sponsor's estimate)
Start
Aug 14, 2025
Primary completion
Jan 2029
Study completion Jun 2029
Sponsor
- Lead sponsor
- Shanghai Zhimeng Biopharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.
Conditions
- Focal Epilepsy
Interventions
CB03-154Drug
All enrolled subjects will begin with a two-week course of CB03-154 at 10 mg QD. Upon demonstrating good tolerability, the dose will be increased to 20 mg QD and continued for up to two years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the long-term tolerability and safety of CB03-154 in patients diagnosed with epilepsy.Time frame: In the entire period of the whole study, including a treatment period up to 2 years (104 weeks) and a post treatment follow-up period of 8 weeks.
- To assess the long-term efficacy of CB03-154 in patients diagnosed with epilepsy.Time frame: In the entire period of the whole study, including a treatment period up to 2 years (104 weeks) and a post treatment follow-up period of 8 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Alfred Health
Melbourne, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.